No title
Background: Lung cancer screening excludes individuals not considered at an increased risk for lung cancer, as predicted by risk models like the Liverpool Lung Project version 3 (LLPv3). In this study, we sought to validate whether plasma glycosaminoglycan profiles (GAGomes) could predict lung cancer independent of LLPv3 and other prespecified comorbidities. Methods: In this retrospective cohort-b
